Articles

Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors

Peking University Cancer Hospital and Institute, Beijing
Fudan University Shanghai Cancer Center, Shanghai
The Affiliated Tumor Hospital of Harbin Medical University, Harbin
The First Affiliated Hospital of Soochow University, Suzhou
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Guangdong Provincial Peoples Hospital, Guangzhou
The Fourth Hospital of Hebei Medical University, Shijiazhuang
Peking University Third Hospital, Beijing
Henan Cancer Hospital, Zhengzhou
Beijing Shijitan Hospital Affiliated of Capital Medical University, Beijing
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan
West China Hospital of Sichuan University, Chengdu
Zhejiang Cancer Hospital, Hangzhou
The First Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou
Hunan Cancer Hospital, Changsha
Fujian Medical University Union Hospital, Fuzhou
HUTCHMED Limited, Shanghai
HUTCHMED Limited, Shanghai
HUTCHMED Limited, Shanghai
HUTCHMED Limited, Shanghai
HUTCHMED Limited, Shanghai
HUTCHMED Limited, Shanghai
HUTCHMED Limited, Shanghai
HUTCHMED Limited, Shanghai
Peking University Cancer Hospital and Institute, Beijing
Haematologica Early view Jan 18, 2024 https://doi.org/10.3324/haematol.2022.282401